What is it used for?
FYARRO® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).FYARRO® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- sirolimus protein-bound particlessirolimus protein-bound particles
- Form and strength
- INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION · 5 mg / 1 mLINJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION · 5 mg / 1 mL
- Manufacturer / applicant
- AADI BIOSCIENCE, INC.AADI BIOSCIENCE, INC.
For injectable suspension: white to yellow, sterile lyophilized powder containing 100 mg of sirolimus formulated as albumin-bound particles in single-dose vial for reconstitution.For injectable suspension: white to yellow, sterile lyophilized powder containing 100 mg of sirolimus formulated as albumin-bound particles in single-dose vial for reconstitution.
Safety and clinical review
- StomatitisStomatitis
- MyelosuppressionMyelosuppression
- InfectionsInfections
- HypokalemiaHypokalemia
- HyperglycemiaHyperglycemia
- Interstitial Lung Disease / Non-Infectious PneumonitisInterstitial Lung Disease / Non-Infectious Pneumonitis
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is FYARRO used for?
FYARRO® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).FYARRO® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of FYARRO should I ask about?
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION · 5 mg / 1 mLINJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION · 5 mg / 1 mL
Read the primary sourceWhat determines the price of FYARRO?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using FYARRO?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.